Access Accelerated Initiative

Partnership Objectives

Access Accelerated is a global initiative to address the rise of NCDs. Its overarching aim is to work towards the United Nations Sustainable Development Goal target to reduce premature deaths from NCDs by one-third by 2030.

80% of NCD-related deaths occur in low and middle-income countries. 80% of NCD-related deaths occur in low and middle-income countries. Copyright Access Accelerated

What are the health needs and challenges?

Non-communicable diseases (NCDs) such as cancer, cardiovascular diseases, chronic respiratory diseases, diabetes and mental health disorders are the leading cause of death and disability worldwide.  The issue of NCDs has reached a crisis point, particularly in low and middle-income countries where 80% of NCD-related deaths occur. Often, this is a result of barriers, such as a lack of trained healthcare professionals, that limit access to care. The fatality rate from NCDs is expected to nearly double by 2030, placing an even greater burden on communities and economies around the world already combating infectious diseases. The Access Accelerated initiative aims to tackle this burden.

Description of partnership activities and how they address needs and challenges

Access Accelerated is a multi-stakeholder collaboration involving 22 biopharmaceutical companies working with partners to help overcome access barriers to NCD medicines in LMICs. Access Accelerated supports on-the-ground work to improve NCD prevention, diagnosis and treatment.

The initiative was launched at the World Economic Forum 2017 and will run as an initial three-year commitment to develop, measure and replicate sustainable programs in LMICs.  By building on long-standing individual company programs in global health, many of which feature on the IFPMA Directory, Access Accelerated will address a variety of access barriers to NCD prevention, treatment and care. With the help of independent experts at Boston University, the efforts made will be evaluated to establish a framework for progress and measure effectiveness.

Thanks to the support of partner World Bank Group, the initiative will also identify solutions to address financing, regulatory and service delivery barriers at country level.

In addition, Access Accelerated will set up partnerships with organizations specializing in major NCDs, starting with cancer. Cancer is a prime example of an NCD for which disease awareness, screening and early diagnosis are key to treatment. As part of this effort, a coalition of companies will be the founding partners of the UICC’s C/Can 2025. In 2017, C/Can 2025 will engage cities around the world to improve cancer treatment and care, working specifically with cities in LMICs which require international support to deliver effective, sustainable cancer care. 


Access Accelerated

Partnership information

Company(ies) Almirall , Astellas , Bayer , Bristol-Myers Squibb , Celgene , Chugai , Daiichi Sankyo , Eisai , Eli Lilly and Company , GlaxoSmithKline , IFPMA , Johnson & Johnson , Menarini , Merck , MSD , Novartis , Pfizer , Roche , Sanofi , Shionogi , Takeda , UCB

Partner(s) Biotechnology Industry Organization (BIO), European Federation of Pharmaceutical Industries and Associations (EFPIA), Japan Pharmaceutical Manufacturers Association (JPMA), Menarini, PhRMA, Sumitomo, Union for International Cancer Control (UICC), World Bank

Type of Partner(s) IGOs, NGOs, Other Business, Professional Associations

Therapeutic Focus Non-Communicable Diseases

Disease(s) Arthritis & Osteoperosis, Asthma, Atrial Fibrillation, Autoimmune Diseases, Breast Cancer, Cancer, Cardiovascular Diseases, Cervical Cancer, Childhood Cancers, Chronic kidney disease, Diabetes, Diseases of the Nervous System, Fistula, Haemophilia, Hematology Disorders, Hypertension, Leukemia, Mental Health, Respiratory Diseases, Sickle Cell Anemia, Thrombotic diseases, Tobacco Control

Program Type(s) Availability of Treatment - Differential Pricing, Availability of Treatment - NCDs Access Programs, Availability of Treatment - Product Donations, Health System Infrastructure - Outreach & Medical Services, Health System Infrastructure - Training, Prevention Programs - Awareness & Outreach

Region(s) World

Number of Countries 1

Country(ies) Worldwide

Start Date 2017

More information Access Accelerated

Anticipated completion date Ongoing

« Through the commitment and expertise of the Access Accelerated partners, we will work towards a shared vision where no person dies prematurely from a preventable, treatable disease. »

Ian Read, Chief Executive Officer of Pfizer and President of The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)